Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
11
2021
accepted:
23
02
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
15
4
2022
Statut:
epublish
Résumé
Pseudomonas aeruginosa is a persistent and difficult-to-treat pathogen in many patients, especially those with Cystic Fibrosis (CF). Herein, we describe a longitudinal analysis of a series of multidrug resistant (MDR) P. aeruginosa isolates recovered in a 17-month period, from a young female CF patient who underwent double lung transplantation. Our goal was to understand the genetic basis of the observed resistance phenotypes, establish the genomic population diversity, and define the nature of sequence evolution over time. Twenty-two sequential P. aeruginosa isolates were obtained within a 17-month period, before and after a double-lung transplant. At the end of the study period, antimicrobial susceptibility testing, whole genome sequencing (WGS), phylogenetic analyses and RNAseq were performed in order to understand the genetic basis of the observed resistance phenotypes, establish the genomic population diversity, and define the nature of sequence changes over time. The majority of isolates were resistant to almost all tested antibiotics. A phylogenetic reconstruction revealed 3 major clades representing a genotypically and phenotypically heterogeneous population. The pattern of mutation accumulation and variation of gene expression suggested that a group of closely related strains was present in the patient prior to transplantation and continued to change throughout the course of treatment. A trend toward accumulation of mutations over time was observed. Different mutations in the DNA mismatch repair gene mutL consistent with a hypermutator phenotype were observed in two clades. RNAseq performed on 12 representative isolates revealed substantial differences in the expression of genes associated with antibiotic resistance and virulence traits. The overwhelming current practice in the clinical laboratories setting relies on obtaining a pure culture and reporting the antibiogram from a few isolated colonies to inform therapy decisions. Our analyses revealed significant underlying genomic heterogeneity and unpredictable evolutionary patterns that were independent of prior antibiotic treatment, highlighting the need for comprehensive sampling and population-level analysis when gathering microbiological data in the context of CF P. aeruginosa chronic infection. Our findings challenge the applicability of antimicrobial stewardship programs based on single-isolate resistance profiles for the selection of antibiotic regimens in chronic infections such as CF.
Sections du résumé
BACKGROUND
Pseudomonas aeruginosa is a persistent and difficult-to-treat pathogen in many patients, especially those with Cystic Fibrosis (CF). Herein, we describe a longitudinal analysis of a series of multidrug resistant (MDR) P. aeruginosa isolates recovered in a 17-month period, from a young female CF patient who underwent double lung transplantation. Our goal was to understand the genetic basis of the observed resistance phenotypes, establish the genomic population diversity, and define the nature of sequence evolution over time.
METHODS
Twenty-two sequential P. aeruginosa isolates were obtained within a 17-month period, before and after a double-lung transplant. At the end of the study period, antimicrobial susceptibility testing, whole genome sequencing (WGS), phylogenetic analyses and RNAseq were performed in order to understand the genetic basis of the observed resistance phenotypes, establish the genomic population diversity, and define the nature of sequence changes over time.
RESULTS
The majority of isolates were resistant to almost all tested antibiotics. A phylogenetic reconstruction revealed 3 major clades representing a genotypically and phenotypically heterogeneous population. The pattern of mutation accumulation and variation of gene expression suggested that a group of closely related strains was present in the patient prior to transplantation and continued to change throughout the course of treatment. A trend toward accumulation of mutations over time was observed. Different mutations in the DNA mismatch repair gene mutL consistent with a hypermutator phenotype were observed in two clades. RNAseq performed on 12 representative isolates revealed substantial differences in the expression of genes associated with antibiotic resistance and virulence traits.
CONCLUSIONS
The overwhelming current practice in the clinical laboratories setting relies on obtaining a pure culture and reporting the antibiogram from a few isolated colonies to inform therapy decisions. Our analyses revealed significant underlying genomic heterogeneity and unpredictable evolutionary patterns that were independent of prior antibiotic treatment, highlighting the need for comprehensive sampling and population-level analysis when gathering microbiological data in the context of CF P. aeruginosa chronic infection. Our findings challenge the applicability of antimicrobial stewardship programs based on single-isolate resistance profiles for the selection of antibiotic regimens in chronic infections such as CF.
Identifiants
pubmed: 35358221
doi: 10.1371/journal.pone.0265129
pii: PONE-D-21-35251
pmc: PMC8970513
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0265129Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002548
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI063517
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI100560
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI072219
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Mol Biol Evol. 2020 May 1;37(5):1394-1406
pubmed: 31851309
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Nat Commun. 2019 Feb 15;10(1):762
pubmed: 30770834
Trends Microbiol. 2016 May;24(5):327-337
pubmed: 26946977
Mol Biol Evol. 1986 Sep;3(5):418-26
pubmed: 3444411
PLoS Biol. 2019 May 30;17(5):e3000291
pubmed: 31145726
Antibiotics (Basel). 2021 Jan 04;10(1):
pubmed: 33406652
Appl Environ Microbiol. 2008 Jun;74(11):3490-6
pubmed: 18378649
Bioinformatics. 2014 Jul 15;30(14):2068-9
pubmed: 24642063
Proc Natl Acad Sci U S A. 2011 May 3;108(18):7481-6
pubmed: 21518885
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Nucleic Acids Res. 2017 Jan 4;45(D1):D566-D573
pubmed: 27789705
Sci Rep. 2019 Nov 21;9(1):17251
pubmed: 31754169
J Clin Microbiol. 2014 Jan;52(1):139-46
pubmed: 24172157
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
J Heart Lung Transplant. 2007 Sep;26(9):890-7
pubmed: 17845927
Nature. 2018 Aug;560(7719):494-498
pubmed: 30089906
Nat Microbiol. 2019 Oct;4(10):1627-1635
pubmed: 31209306
Antimicrob Agents Chemother. 2019 Mar 27;63(4):
pubmed: 30745381
Microbiology (Reading). 2007 May;153(Pt 5):1445-1454
pubmed: 17464058
Infect Immun. 1994 Feb;62(2):596-605
pubmed: 8300217
Science. 2018 Nov 9;362(6415):
pubmed: 30409860
Nat Commun. 2019 Jan 18;10(1):334
pubmed: 30659188
Nucleic Acids Res. 2012 May;40(10):4288-97
pubmed: 22287627
Cell Host Microbe. 2015 Sep 9;18(3):307-19
pubmed: 26299432
Mol Microbiol. 2005 Apr;56(2):309-22
pubmed: 15813726
Bioinformatics. 2015 Nov 15;31(22):3691-3
pubmed: 26198102
PLoS Biol. 2019 Oct 23;17(10):e3000397
pubmed: 31644535
Mol Biol Evol. 1987 Jul;4(4):406-25
pubmed: 3447015
Microb Drug Resist. 2017 Jan;23(1):51-55
pubmed: 27326758
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Nat Microbiol. 2016 May 09;1(6):16053
pubmed: 27572838
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Infect Immun. 1984 Jul;45(1):197-202
pubmed: 6429045
Infect Immun. 1994 Aug;62(8):3506-14
pubmed: 8039921
Genome Biol. 2014;15(11):524
pubmed: 25410596
Genome Res. 2008 May;18(5):821-9
pubmed: 18349386
Nat Genet. 2015 Jan;47(1):57-64
pubmed: 25401299
Int J Med Microbiol. 2017 Sep;307(6):353-362
pubmed: 28754426
BMC Genomics. 2018 Apr 4;19(1):234
pubmed: 29618320
Front Microbiol. 2021 Apr 07;12:604555
pubmed: 33897629
Microbiology (Reading). 2010 Apr;156(Pt 4):1108-1119
pubmed: 20019078
Fly (Austin). 2012 Apr-Jun;6(2):80-92
pubmed: 22728672
Nat Commun. 2021 May 27;12(1):3186
pubmed: 34045458
Nature. 2000 Aug 31;406(6799):959-64
pubmed: 10984043
Nat Microbiol. 2020 Mar;5(3):455-464
pubmed: 32042129
Sci Transl Med. 2013 Sep 25;5(204):204ra132
pubmed: 24068739
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
J Cyst Fibros. 2015 Jan;14(1):70-77
pubmed: 25027418
Nucleic Acids Res. 2019 Jan 8;47(D1):D419-D426
pubmed: 30407594
Nucleic Acids Res. 2019 Jan 8;47(D1):D330-D338
pubmed: 30395331
Proc Natl Acad Sci U S A. 2021 Feb 2;118(5):
pubmed: 33441451
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
Nature. 2012 Jul 04;487(7405):109-13
pubmed: 22763554
Am J Respir Crit Care Med. 2015 Apr 1;191(7):775-85
pubmed: 25590983
Transpl Infect Dis. 2014 Aug;16(4):666-71
pubmed: 24964912